Market Segmentation:
- By Treatment Type
- Gene Therapy
- Symptomatic Treatment
- Antioxidants
- Others
- By Route of Administration
- Oral
- Injectable
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By End-User
- Hospitals
- Clinics
- Research Institutes
- Others
- By Regions
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Frequently Asked Questions
The current market size is estimated at USD 1.2 billion in 2023.
Increasing research into gene and molecular therapies, Advances in genetic screening and diagnostics, Special regulatory incentives for rare disease drug development, Rising clinical trial activity, Improving healthcare infrastructure globally, Increasing patient advocacy groups and funding
The leading component segment in the Friedreich’s Ataxia Market is the gene therapy segment. Gene therapy aims to address the underlying genetic cause of Friedreich's ataxia and has curative potential.
The market is projected to grow at a CAGR of 5.8% from USD 1.2 billion in 2023 to USD 1.9 billion by 2031.
Increasing research into gene therapy and molecular treatments, Advancing genetic screening and diagnostics, Regulatory incentives for rare disease drug development, Rising pharmaceutical industry interest and clinical trial activity, Improving healthcare access globally, Patient advocacy groups and funding.